Valink Therapeutics Analysis
What is Valink Therapeutics?
Valink Therapeutics develops bispecific antibody-drug conjugates (bsADCs) for targeted cancer treatment, enhancing drug delivery and selectivity.
Location
Cambridge, United States
Employees
14
Founded
2021
Revenue
$0-1M
Product Features & Capabilities
- bispecific antibody drug conjugates (bsADCs), rapid design of drug candidates, LiliumX™ discovery platform, dual targeting for improved function, targeting solid tumors, enhanced payload delivery
Use Cases
Develop bispecific ADCs for treating CRC; Advance oncology programs for NSCLC; Create drugs targeting pan-cancer indications; Minimize side effects in cancer therapies; Explore new payloads for drug delivery
Who are the founders of Valink Therapeutics
AS
Arne Scheu
Founder
IK
Irsyad Khairil
Founder
Market Focus
Valink Therapeutics primarily focuses on the biotechnology industry, specifically in the development of bispecific antibody drug conjugates (bsADCs) for targeted cancer treatments.
Investors
- P53
- Metaplanet
- Metaplanet Holdings
- RV Invest
- SynBioVen
- Oxonian Ventures
- Acequia Capital
- Hoxton Ventures
- Magnet Capital
Business Model
Bootstrapped revenue model focusing on funding and partnerships for drug development.
Competitors Overview
Valink Therapeutics operates in the bispecific antibody drug conjugate (bsADC) market, which is competitive and includes several notable players. Key competitors include:
- Amgen: A major biopharmaceutical company known for its extensive research capabilities and a strong pipeline of bispecifi
Other Considerations
Closed $11.8 million Pre-A financing round; Appointed biopharmaceutical veteran Martin D. Williams as Chair; Presentations at major industry events; Active pipeline with multiple oncology programs
See something that needs updating? Suggest edits to this profile.